Showing results (1-10 of 7) with videos related to
Sort By:
Pageof 1
Frontiers in Health Services|September 11, 2023
A theory on ICER pricing and optimal levels of cost-effectiveness thresholds: a bargaining approachMikel Berdud, Jimena Ferraro, Adrian TowseCost Effectiveness and Resource Allocation : C/E|September 10, 2020
Establishing a reasonable price for an orphan drugMikel Berdud, Michael Drummond, Adrian TowseGaceta Sanitaria|June 21, 2016
Incentives and intrinsic motivation in healthcareMikel Berdud, Juan M Cabasés, Jorge NietoPharmacoeconomics|January 22, 2016
Biosimilars: How Can Payers Get Long-Term Savings?Jorge Mestre-Ferrandiz, Adrian Towse, Mikel BerdudValue in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|February 4, 2023
The Allocation of the Economic Value of Second-Generation Antipsychotics Over the Product Life Cycle: The Case of Risperidone in Sweden and the United KingdomMikel Berdud, Niklas Wallin-Bernhardsson, Bernarda Zamora, et al.Health Affairs Scholar|November 13, 2025
Understanding biopharmaceutical investment decision-making: how does Congressional Budget Office's model compare to investor insights?Matthias P Hofer, Priscila Radu, Mikel Berdud, et al.The American Journal of Managed Care|November 1, 2017
What do pharmaceuticals really cost in the long run?Darius Lakdawalla, Joanna P MacEwan, Robert Dubois, et al.Pageof 1